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and results
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Division of Cardiovascular Surgery, University Hospital, Zurich, Switzerland
Summary
Mitral valve insufficiency is the second most common
heart valve disease and untreated regurgitation leads to en-
largement of the left atrium, atrial fibrillation and heart
failure. Besides functional regurgitation, the main cause is
degenerative valve disease with elongation of the chordae
tendineae and prolapsing of the leaflets. Surgical repair
is the gold standard therapy for mitral valve insufficiency
today. Numerous techniques have been described. Pro-
posed techniques are resection of the prolapsed segment,
chordae transfer and ring annuloplasty. Lately, the implant-
ation of neochordae and the loop-technique has been estab-
lished and is the preferred technique in many centres.
There is ongoing discussion about the ideal timing for the
intervention in asymptomatic patients. Some groups prefer
a watchful waiting strategy; others promote an early inter-
vention, which is also recommended in the guidelines.
Results of surgical mitral valve repair are good with low
rates of re-intervention and mortality. With minimally in-
vasive techniques, the patient satisfaction is high and hos-
pital stay is short.
In conclusion, mitral valve repair should be the preferred
strategy in patients with symptomatic mitral valve insuffi-
ciency or with asymptomatic mitral valve insufficiency in
accordance with the guidelines. Modern repair techniques
such as neo-chord implantation with the loop-technique
combined with minimally invasive access routes result in
low mortality and morbidity and short hospital stay as well
as high patient satisfaction.
Key words: mitral valve repair; loop technique; minimally
invasive mitral valve repair; timing of mitral valve repair
Introduction
Mitral valve (MV) reconstruction is the gold standard for
the treatment of MV regurgitation (MR) today [1]. There is
currently no reasonable alternative to surgery which is cur-
ative and results in the prevention of subsequent heart fail-
ure [2]. Mitral valve reconstruction has been demonstrated
to be superior to MV replacement with improved post-op-
erative survival rates and preserved left ventricular func-
tion [3, 4].
The MV is a complex structure based upon five different
components: the mitral annulus, the anterior and posterior
leaflet, the chordae tendinae, the papillary muscles and the
left ventricle. A complex mechanism underlies the systol-
ic and diastolic function of the MV. The two highest pre-
valence entities are primary (degenerative) and secondary
(functional) MR. In primary MR, elongation or rupture
of chordae tendineae and/or excessive tissue lead to re-
pulsing or prolapsing of the leaflet into the atrium during
systole with resulting insufficiency. Underlying patholo-
gies are fibroelastic deficiency or myxomatous prolifera-
tion of the leaflet tissue as seen in Barlow’s disease. In sec-
ondary MR ischaemic or idiopathic cardiomyopathy leads
to alterations in the ventricular geometry, the subvalvular
apparatus and of the mitral annular geometry leading to
MR. Therefore, the goal of a mitral valve repair procedure
follows two fundamental principles: restore a sufficient
surface of leaflet coaptation and correction of annular
dilatation.
In daily clinical routine, a lack of adherence to guidelines
addressing the timely referral of patients with indications
for surgery can be observed. One reason might be that it
is not possible to predict the success of MV repair. Addi-
tionally, current medical and surgical practice often seems
to result in suboptimal care for the individual patient with
degenerative mitral valve disease. A better implementation
of education in regards of the guidelines is essential to ad-
vance the field. All cardiovascular specialists should have
familiarity with the up-to-date standards in terms of MV
disease differentiation, timing of intervention and surgical
techniques in order to improve patient care.
Timing
Surgical intervention for chronic severe mitral valve regur-
gitation is usually triggered by the occurrence of symp-
toms, declining LV function, significant LV enlargement or
the development of atrial fibrillation or severe pulmonary
hypertension [5, 6]. Controversy exists about the timing of
surgery in asymptomatic patients: Early surgical interven-
tion before the onset of ventricular changes is preferred in
several centres for patients with severe degenerative mitral
valve disease. Others prefer a watchful waiting strategy. In
the latest guidelines, the best evidence recommendation for
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asymptomatic patients is IC [5, 6]. This debate has put em-
phasis on the lack of predictability of mitral valve repair,
despite broad consensus that this is the procedure of choice
for patients undergoing surgical intervention.
Patients with asymptomatic severe mitral valve
regurgitation
A reason for early surgical correction of mitral valve re-
gurgitation is the existing evidence that the majority of
asymptomatic patients develop symptoms and/or other in-
dications for surgery within 5–10 years of diagnosis.
Enriquez-Sarano et al. described high event rates in a series
of asymptomatic patients with quantitatively graded severe
degenerative mitral regurgitation (effective regurgitant ori-
fice area ≥40 mm2). These results lead them to recommend
prompt surgery in this patient cohort [7].
Rosenhek et al. published a series of 132 asymptomatic pa-
tients with severe degenerative mitral regurgitation. They
applied a watchful waiting strategy and noted a good out-
come. Within an 8-year interval, 45% of patients had an
event (but not sudden death), with events occurring at a
regular pace. Twenty four of 36 patients fulfilling indica-
tions for surgery became symptomatic. The rest required
surgery because of asymptomatic LV dysfunction or en-
largement, new onset atrial fibrillation or pulmonary hy-
pertension [8]. Kang et al. published a study including 161
asymptomatic patients with severe degenerative mitral re-
gurgitation who were subjected to early surgery, compared
to 268 patients managed by watchful waiting over a nine
year follow-up. A 99% cardiac event-free survival was ob-
served in operated patients, compared with 85% in patients
under a strategy of continued medical observation. Urgent
surgery was proposed but refused by five of the six patients
who died of congestive heart failure and one sudden death
occurred in a patient who had become symptomatic. Three
cases of sudden death occurred in asymptomatic patients
[9]. Montant and colleagues investigated in a study the out-
comes in patients with severe degenerative mitral regurgit-
ation by semi-quantitative echocardiographic assessment,
reporting on 67 patients managed with a conservative ap-
proach and 125 patients subjected to early mitral valve re-
pair. Ten year survival was significantly lower in conser-
vatively managed patients compared with those operated
early [10].
Several prognostic factors allowing risk stratification for
asymptomatic patients have been proposed. High levels
of brain natriuretic peptide (<105 pg/mL) were associated
with an unfavourable outcome in a study by Pizzaro and
colleagues [11]. Recently, Tribouilloy and colleagues have
shown that a LV end-systolic diameter (LVED) ≥40 mm
is independently associated with increased mortality under
medical management and after surgery [12]. The LVESD
is also a parameter that is used in the guidelines for re-
commendations for surgery. Recent European guidelines
recommend referral for surgery when the LVESD is larger
than 45 mm compared to North American guidelines with
recommendations for surgery in LVED diameters larger
than 40 mm [5, 6].
There is evidence, that early mitral valve repair is bene-
ficial according to left ventricular function. A study by
Suri and colleagues has shown superior recovery of left
ventricular ejection fraction after early mitral valve repair
in patients with an preoperative ejection fraction of ≥65%
[13].
In accordance with the current guidelines, surgery is indic-
ated in asymptomatic patients with LV dysfunction defined
by an ejection fraction below 60% or a left ventricular end
systolic diameter of 45 mm or more (Class I, Level C). Sur-
gery is recommended to be considered in asymptomatic pa-
tients with preserved LV function, new onset of atrial fib-
rillation or pulmonary hypertension (Class IIa, Level C),
preserved LV function, high likelihood of durable repair,
low surgical risk and flail leaflet and increased LVESD
(Class IIa, Level C) and maybe considered in asymptomat-
ic patients with preserved LV function, high likelihood of
durable repair, low surgical risk and left atrial dilatation
and sinus rhythm or pulmonary hypertension on exercise
(Class IIb, Level C) (table 1) [5].
Patients with symptoms and/or left ventricular
dysfunction
There are clear recommendations for surgery in current
guidelines for patients with symptoms of left ventricular
dysfunction [5, 6]. In contrast in daily clinical business
there seems to be discordance to the guidelines. Several
Table 1: Guideline recommendations for indications for surgery in severe primary mitral regurgitation. Adapted from: Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Barón-
Esquivias G, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the
European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2012;33:2451–96 [5].
Class Level
Mitral valve repair should be the preferred technique when it is expected to be durable. I C
Surgery is indicated in sympotmatic patients with LVEF >30% and LVESD <55 mm. I B*
Surgery is indicated in asympotmatic patients with LV dysfunction (LVESD ≥45 mm and/or LVEF ≤60%). I C
Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension
(systolic pulmonary pressure at rest >50 mm Hg).
IIa C
Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail
leaflet and LVESD ≥40 mm Hg.
IIa C
Surgery should be considered in patients with severe LV dysfunction (LVEF <30% and/or LVESD >55 mm) refractory to medical therapy with high
likelihood of durable repair and low comorbidity.
IIa C
Surgery may be considered in patients with severe LV dysfunction (LVEF <30% and/or LVESD >55 mm) refractory to medical therapy with low
likelihood of durable repair and low comorbidity.
IIb C
Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and - Left atrial
dilatation (volume index ≥60 ml/m2 BSA) and sinus rhythm, or - Pulmonary hypertension on exercise (SPAP ≥60 mm Hg at exercise).
IIb C
BSA = body surface area; LV = left ventricle; LVEF = left ventricular ejection fraction; LVESD = left ventricular end-systolic diameter; SPAP = systolic pulmonary artery
pressure; class = class of recommendation; level = level of evidence; * references supporting class I(A+B) and IIa+IIb (A+B) recommendations: [14, 15].
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studies found that numerous patients with indications for
surgery received no operation. Mirabel and colleagues
found that 49% of patients with symptomatic mitral valve
regurgitation from the Euro Heart Survey were not referred
for surgery due to advanced age, co-morbidities and an de-
creased ejection fraction [16]. In the same patient cohort,
Detaint and colleagues later identified 101 patients with
severe mitral regurgitation. They found that 29% have not
received intervention although they had no relevant co-
morbidities and fulfilled guideline recommendation criteria
for surgery [17]. They considered the relatively low level
of evidence as the underlying cause for denial of referral.
Toledano and colleagues surveyed Canadian cardiologists
and found that nearly 40% of those indicated that they
would wait with the referral of an asymptomatic patient
with severe mitral valve regurgitation for surgery until the
ejection fraction fell below 40% or symptoms occur. The
decrease in LVEF was considered as clearly underestim-
ated by the cardiologists in this study [18]. In conclusion, it
has been demonstrated that referral for surgery in patients
with symptomatic MR is not in accordance with the
guidelines in up to 50%. The underlying causes are multi-
factorial. An underestimation of the decrease of the LVEF
has been considered as factor as well as the underuse of
current guidelines due to lower level of evidence. Addi-
tionally, referral of patients has been demonstrated to be
more in accordance with the guidelines when physicians
that have graduated later are the referring person. These
data show that there is need for continued medical educa-
tion of practicing clinicians to increase familiarity with cur-
rent guidelines.
Surgical techniques
Surgical access
The classical access for mitral valve repair is full median
sternotomy. Besides smaller accesses such as partial sterno-
tomy, the right lateral thoracotomy (fig. 1) is used in many
expert centres today. In regards of mortality, excellent short
and long-term results are described [19–21]. Patients bene-
fit from better cosmetic results and less blood transfusion
has been reported in some series. On the other hand this
may come at an expense of increased cardiopulmonary by-
pass time and longer cross-clamp and procedure times [22].
Figure 1
Positioning of the patient for minimally invasive access: the Zurich
approach.
A modification is the endoscopic technique also performed
through a thoracotomy but without the use of a thoracic
retractor and without direct vision [23]. In specialised
centres, the mitral valve is repaired totally endoscopically
with the use of the da Vinci system [24].
A consensus statement of the International Society for
Minimally Invasive Cardiothoracic Surgery (ISMICS)
gives an evidence class IIb recommendation for minimally
invasive surgery in patients with mitral valve disease. This
recommendation is based on comparable short and long
term mortality, in hospital morbidity, reduced sternal com-
plications, blood transfusion, atrial fibrillation and reduced
ventilation time, intensive care unit stay and length of hos-
pital stay standing against an increased risk of stroke, aortic
dissection, phrenic nerve lesion and prolonged cross clamp,
cardiopulmonary bypass and procedure time [25].
Taking all factors into calculation it seems that the minim-
ally invasive or port-access approach is at least as good and
safe as the conventional sternotomy approach but there is
still a lack of prospective, randomized controlled trials with
Figure 2
Gore-Tex loop technique and ring annuloplasty; Fibroelastic
deficiency with prolapse of the anterior leaflet; Gore-Tex loops are
constructed, and the apparatus is attached to the fibrous tip of the
papillary muscle. Individual loops are attached to the prolapsing
segment margin and completed repair after ring annuloplasty.
Figure 3
Measurement of the length for the artificial chords. implanted chord
and the complete neo-chord as available from the manufacturer.
Review article: Current opinion Swiss Med Wkly. 2012;142:w13715
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 3 of 9
adequate patient numbers and follow up times to determine
the balance of benefits and risks.
The only contraindication for minimally invasive access is
severe calcification of the annulus. Debridement of calci-
fied tissue is required to restore a good mobility to leaflet
tissue and to ensure an adequate surface of coaptation.
However special instruments are necessary that are not
available for minimally invasive techniques and access is
very limited. Severe complications such as ventricle rup-
ture can occur that cannot be managed so well through the
minimally invasive access.
Repair techniques
Three principle goals of MV repair were introduced by
Carpentier: Stabilisation of the annulus with the retention
of an adequately sized mitral orifice, restoration of
physiological leaflet motion and recreation of a sufficient
line of coaptation. The first technique to reach this was the
so-called “French correction” introduced in 1983.
A resection of redundant tissue, chordal transfer, chordal
shortening and remodelling annuloplasty were parts of the
operation described by Carpentier and colleagues [26].
This ‘classical’ repair technique has been demonstrated to
result in excellent outcome with a high durability and high
freedom from reoperation rate [1, 20, 21, 27, 28].
The paradigm of ‘respect rather than resect’ tissue emerged
in recent years. Use of polytetrafluoroethylene (PTFE) neo-
chordae was introduced to support fixation of the free edge
of prolapsing segments and ‘displacing’ abnormal excess
tissue into the ventricle to ensure a good surface of coapt-
ation instead of resection of leaflet tissue [29]. A variation
of this technique is the ‘loop technique’ where the PTFE
is anchored into the tip of the papillary muscle and ‘loops’
are attached to the free edge mimicking a chordal fan (fig.
2) [30, 31]. The neochordae are anchored on the anterior
or posterior papillary muscle in their fibrous portion. It’s
important that crossing the midline or individual native
chordae is avoided in order to prevent excess traction on
the leaflet margin. In the case of significant excess posteri-
or leaflet height, the neochordae are made short enough to
displace the prolapsing segment into the left ventricle, to
ensure a large surface of coaptation for the anterior leaflet
while preventing anterior leaflet displacement in the out-
flow tract. Exact measurement is necessary before implant-
ation. The relevant length is measured from the tip of the
papillary muscle to intended coaptation line (fig. 3). No or
limited leaflet resection in combination with PTFE loops is
now a preferred technique in our and many other centres.
In all mitral valve reconstructions a prosthetic ring or band
annuloplasty is used to restore the normal circumference
and shape of the mitral valve to match the available leaflet
tissue [32]. The fibrous skeleton of the heart and long-
standing regurgitation associated with ventricular and atrial
enlargement leads to dilatation of the mitral annulus, par-
ticularly along the posterior aspect of the valve. To have
an idea of the appropriate ring size, measurement of the
surface of the anterior leaflet with a seizer is used to es-
timate the appropriate ring size for the amount of leaflet
tissue. This may have important implications for percu-
taneous techniques that primarily attempt to address pro-
lapse by attaching opposing leaflets without concomitantly
changing the shape of the annulus.
For patients with secondary MR, undersized mitral annu-
loplasty is the current surgical gold standard. This strategy
tempts to reshape the mitral annulus to a more anatomically
correct form, thus leading to increased leaflet coaptation
and a ompetent MV. Important for this operation is the
implantation of a complete rigid annuloplasty ring, rather
than an open flexible band [33, 34]. Undersized annulo-
plasty has been associated with left ventricular reverse re-
modelling and improvement of symptoms in the majority
of patients, but recurrent MR occurs more frequently than
in patients with degenerative disease. Recently developed
strategies such as the ‘ring and string’ concept, secondary
chordal cutting, septal-lateral banding and posterior leaflet
extension have been suggested as additional techniques
that may minimise the risk of recurrent MR [35, 36].
Numerous additional repair techniques such as the edge-to-
edge repair, papillary muscle shortening, leaflet reduction
plasty and others have been developed, affording the sur-
geon a wide armamentarium of approaches [37–40]
Today, several evolving technologies are arising to over-
come challenges such as the need to perform the operation
on the arrested heart under non-physiological conditions.
The estimation of the result of the reconstruction is diffi-
cult. Due to this the outcome of a MV repair is strongly de-
pendent to the caseload of the performing centres and the
experience of the surgeons [41, 42]. New devices were in-
troduced lately focusing on overcoming these pitfalls and
intending to improve operative results and provide tech-
niques to avoid the CPB. These devices have features to
adjust the diameter or length of annuloplasty rings or neo-
chordae, respectively. Animal experiments showed prom-
ising results and clinical trials are running at present [43,
44].
Results
Modern cardiac surgery programmes with a high volume
number have achieved very high and durable MV repair
rates with minimal perioperative mortality and long-term
outcomes that are comparable with the general population.
Braunberger and colleagues described their very long term
results with follow up periods of more than 20 years. 162
patients were included, mainly operated due to degenerat-
ive MV disease (90%) or endocarditis (10%). The classical
French correction technique was used. After three months
the MV reoperation rate was below two percent. Within
the 20 years follow-up only seven patients had to under-
go repeat MV operation. The survival rate was around 50%
comparable to the survival rate of the normal population
with that age structure [27]. Seeburger and colleagues de-
scribed the results of 1,339 patients who had undergone
minimally invasive mitral valve repair in a time period of
eight years. Success rate was almost 100%. The five year
Kaplan-Meier estimation for freedom from MV reopera-
tion was 96.3%. Thirty day mortality was 2.4% and the five
year survival was 82.6% [21]. The same group investigated
the outcome of MV repair focusing on different underly-
ing degenerative forms. Around half of the patients were
treated for posterior leaflet prolapse. The other half of pa-
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tients had to undergo surgery for anterior or bileaflet pro-
lapse. The repair rate was 94%. Freedom from reoperation
rate at five years was 95.6%. The thirty days mortality was
1.8% and the five-year survival was 87.3% in this patient
cohort. No significant differences in outcome and duration
of the repair were observed in regards of the different un-
derlying prolapse [1].
Slightly different results were described by David and col-
leagues. More than 700 patients were included with MR
due to prolapsing of anterior, posterior or bileaflet prolapse.
The distribution of the location of the prolapse was similar
to the work of Seeburger and colleagues described above.
In contrast the results for the repair of anterior leaflet pro-
lapse and bileaflet prolapse were worse than for posterior
leaflet prolapse. The freedom from reoperation rate was
96% for posterior leaflet repair compared to 94% of both
leaflets repair and 88% of anterior leaflet repair. The
follow-up period was 12 years and the survival at this time
was 75% [20].
These superb results can also be achieved through a minim-
al invasive technique leading to a better cosmetic result, a
decreased incidence of respiratory failure, decreased post-
operative pain and a faster recovery [22, 45]. For robotic
supported MV surgery no large randomized trial has been
published to compare totally endoscopic MV repair to port-
access surgery. Chitwood and colleagues presented their
results of 300 mitral valve repairs performed with the da
Vinci system and reported safe performance of the pro-
cedure as well as low short and midterm mortality. 30-day
mortality was below 1%, late mortality was 2%. There was
no conversion to sternotomy, but to conventional port ac-
cess surgery (in 9 of 309 intended-to-treat patients) due to
technical problems with the da Vinci system or the need for
mitral valve replacement. The conclusion of this paper was
that the technique is safe and feasible but longer time fol-
low up is necessary [26].
The outcome of patients undergoing MV repair for sec-
ondary MR is dependent to the underlying cause of cardi-
omyopathy and the concomitant procedure. Gummert and
colleagues described a 30-day mortality rate of 6.1% and
a 5-year survival of 66% in patients with dilated and
ischaemic cardiomyopathy. Tricuspid valve repair and at-
rial fibrillation ablation and atrial size reduction were the
only accepted concomitant procedure [46]. Bax and col-
leagues reported their results for 51 patients undergoing
coronary revascularisation and parallel restrictive MV re-
pair in ischaemic cardiomyopathy. Their early mortality
rate was 5.6% and the 2-year survival was 84%. One pa-
tient had to undergo reoperation for recurrent MR. 2-year
echocardiographic follow-up showed non or mild MR in all
patients as well as a decrease in left ventricular end systol-
ic and end diastolic dimensions [47]. Additionally, differ-
ences in outcome in regards of the use of a complete or a
partial annuloplasty ring have been observed by Kwon and
colleagues. In a retrospective study of 479 patients that had
undergone MV repair due to secondary MR, they found
a greater freedom from recurrent MR in the 209 patients
where a complete ring was used compared to 270 patients
treated with a partial ring. A difference in survival during
the follow-up could not be detected [48].
Conclusions
Current surgical mitral valve repair offers a highly effective
and safe treatment for patients with MR, even in those pa-
tients who require reoperative procedures. Access is either
gained through a full sternotomy or through minimally in-
vasive access such as right sided thoracotomy or partially
and/or totally endoscopically with robot systems. The min-
imally invasive technique shows similar reconstructive res-
ults as open repair. However, the cosmetic results lead to
a higher patient satisfaction and less blood transfusion. In
experienced centres it is the standard approach.
The first repair technique introduced by Carpentier in 1983
was the “French correction” that included leaflet-resection,
chordal replacement and annuloplasty with ring devices.
Starting from there a continuous evolution of the tech-
niques can be observed. To date, neo-chord implantation
additionally to annuloplasty is a preferred technique in
many centres to treat primary mitral valve insufficiency
despite the fact that there is no clear advantage in regards
of mortality or durability of the repair compared to re-
section of prolapsing segments. An explanation might be
that implantation of chords is more straightforward espe-
cially when the operation is performed minimally-invasive
and video-assisted. Additionally this technique permits im-
plantation of larger annuloplasty-rings and a larger area of
coaptation can be achieved [49]. Results show that the im-
provement of the techniques has led to better outcomes in
regards to mortality and to a decrease of reoperation rates
compared to the initial techniques. Different underlying
pathologies are better addressed by introduction of these
new techniques. MR still demonstrates a high potential for
innovative techniques. Adjustable devices were lately in-
troduced to the market and off-pump techniques are under
preclinical and clinical investigation.
The timing for surgical intervention is still a matter of dis-
cussion. The occurrence of symptoms should be a trigger
for referring a patient according to the guidelines. Interest-
ingly, it seems that the referral for surgery is often not in
accordance with the guidelines in patients with severe MR.
Explanations might be the relatively low evidence levels
of the guidelines or underestimations of factors that are
clear triggers for the referral. In asymptomatic patients the
decision finding process is even more difficult. Different
parameters such as left ventricular end-diastolic dimension
and a decrease of left ventricular function are indicators for
the referral to surgery. However there is still controversy
about the preference of a watchful waiting strategy and
early surgery. The evidence-level of the guidelines seems
to leave a confidence gap resulting in uncertainty about
the timing for referral. This shows that there is need for
continued efforts in investigating the outcomes of mitral
valve surgery in different patient cohorts and improve med-
ical education of practicing clinicians to increase familiar-
ity with current guidelines.
In conclusion, the results of mitral valve repair are ex-
cellent and it is widely accepted that a reconstruction is
preferable to a valve replacement. Surgery can result in a
complete correction of the MR and normalisation of valve
morphology and thus represents the only curative treatment
strategy for patients with mitral valve regurgitation. It
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therefore represents the current gold standard for the treat-
ment of mitral valve regurgitation.
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Figures (large format)
Figure 1
Positioning of the patient for minimally invasive access: the Zurich approach.
Figure 2
Gore-Tex loop technique and ring annuloplasty; Fibroelastic deficiency with prolapse of the anterior leaflet; Gore-Tex loops are constructed, and
the apparatus is attached to the fibrous tip of the papillary muscle. Individual loops are attached to the prolapsing segment margin and
completed repair after ring annuloplasty.
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Figure 3
Measurement of the length for the artificial chords. implanted chord and the complete neo-chord as available from the manufacturer.
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